A comprehensive view of merck & co. inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.
European Commission approves Merck’s KEYTRUDA pembrolizumab plus chemotherapy as neoadjuvant treatment, then continued as monotherapy as adjuvant treatment, for resectable non-small cell lung cancer at high risk of recurrence in adults
Published:
March 28, 2024
by Business Wire
|
Merck & Co. Inc. Announces FDA Approval for Pulmonary Arterial Hypertension Treatment, Reinforcing Commitment to PAH Patients and Advancing Clinical Trial Diversity
Published:
March 27, 2024
by Industry Intelligence Inc.
|
Merck's second trial testing Lynparza with Keytruda to treat metastatic non-small cell lung cancer fails to show significant improvement on life expectancy or disease progression; Merck remains committed to exploring Keytruda combinations in lung cancer
Published:
March 21, 2024
by FiercePharma
|
Merck announces plans to develop a new multi-valent HPV vaccine offering broader protection against multiple HPV types; the company will also initiate clinical trials to test the efficacy and safety of a single-dose regimen of Gardasil 9
Published:
March 15, 2024
by PharmaBiz
|
GlobalData expects GLP-1 drugs like Novo Nordisk's Ozempic to become bestselling drug class in 2024, dethroning PD-1 inhibitors like Merck's Keytruda; GLP-1 drugs' expected annual sales of US$50B marks shift in demand from oncology to metabolic disorders
Published:
March 15, 2024
by FiercePharma
|
Ask us about our Health Care Sector market view